Ligand Pharmaceuticals: Q4 Earnings Insights
Benzinga Insights 8 months ago
Earnings
Ligand Pharmaceuticals (NASDAQ:LGND) released its Q4 earnings on Thursday, February 26, 2026 at 07:00 AM.
Here's what's important from the earnings announcement.
Earnings
Ligand Pharmaceuticals beat estimated earnings by 75.65%, reporting an EPS of $2.02 versus an estimate of $1.15.
Revenue was up $16.85 million from the same period last year.
Earnings History Overview
In the previous quarter, the company beat on EPS by $1.52, resulting in a 2.76% drop change in the share price the following day.
Here's a look at Ligand Pharmaceuticals's past performance:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.57 | 0.94 | 1.21 | 1.19 |
| EPS Actual | 3.09 | 1.60 | 1.33 | 1.27 |
| Revenue Estimate | 58.54M | 44.58M | 37.84M | 39.03M |
| Revenue Actual | 115.46M | 47.63M | 45.33M | 42.81M |
To track all earnings releases for Ligand Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
